@AlCp mate, is this seriously not self-explannatory...
If you are unsure what *Preliminary enrollment update; data and number of evaluable patients subject to change with full statistical analysis means, maybe use chat GPT?
It's simply stating the number of patients, efficacy, and statistical analysis that follows is subject to change...
Because the MAST trial is open-label, the responses for the 9 extra patients evaluated are known by IMU.
Do you agree that a complete or partial response would have a material impact on the shareprice?
Good, because the continuous disclosure guidelines for the ASX state that:
The only reasonable conclusion is, thus, there are no extra responses. The more unsettling thing is why haven't IMU told shareholders about it...
@melburnian aren't you showing me where I was wrong 18-20 months before clinical trial results?
@AlCp mate, is this seriously not self-explannatory...If you are...
-
- There are more pages in this discussion • 535 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |